selinexor + rituximab + gemcitabine + dexamethasone + cisplatin

This drug is a **combination therapy** consisting of five agents: selinexor, rituximab, gemcitabine, dexamethasone, and cisplatin. Selinexor is an oral, selective inhibitor of exportin-1 (XPO1), leading to nuclear accumulation of tumor suppressor proteins and downregulation of oncogenic proteins. Rituximab is a monoclonal antibody targeting CD20 on B lymphocytes that mediates cell lysis. Gemcitabine is a nucleoside analog that inhibits DNA synthesis. Dexamethasone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties. Cisplatin is a platinum-based chemotherapeutic agent that crosslinks DNA. The combination is used in relapsed or refractory B-cell lymphomas, notably diffuse large B-cell lymphoma (DLBCL), where it has shown durable efficacy and a generally tolerable safety profile in phase 1b clinical studies[1][3][5][7].

Other names

selinexor + R-GDP